$8.01
0%
Price vs. AI Score (Last 150 days)
Data gathered: December 9
Data gathered: December 9
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | N/A | N/A |
| Sentiment | N/A | N/A |
| Webpage traffic | N/A | N/A |
| Google Adspend | $ N/A | N/A |
| Google Trends | N/A | N/A |
| Patents | N/A | N/A |
| 4chan Mentions | N/A | N/A |
| Facebook Engagement | N/A | N/A |
| Facebook followers | N/A | N/A |
| Stocktwits Mentions | N/A | N/A |
| Stocktwits Subscribers | N/A | N/A |
| Twitter Followers | N/A | N/A |
| News Mentions | N/A | N/A |
| Reddit Mentions | N/A | N/A |
| ESG | N/A | N/A |
In the news
Anavex put volume heavy and directionally bearishDecember 6 - Thefly.com |
|
 |
Alzheimer's Disease Drug Development: Another Lost YearDecember 4 - SeekingAlpha |
 |
Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) and 4D Molecular Therapeutics (NASDAQ:FDMT)December 3 - ETF Daily News |
Noteworthy Monday Option Activity: AVXL, AVAV, CEREDecember 3 - Stock Options Channel |
|
AVXL Makes Bullish Cross Above Critical Moving AverageDecember 3 - Market News Video |
|
 |
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC WainwrightNovember 30 - ETF Daily News |
About Anavex Life Sciences
Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease) More about us.
| Price | $8.01 |
| Target Price | Sign up |
| Market Cap | $658M |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q3 '23 | 1.8M | 2.6M | -820,000 | -10M | -10M |
| Q2 '23 | 1.7M | 3.2M | -1.5M | -11M | -11M |
| Q1 '23 | 1.3M | 2.9M | -1.5M | -13M | -14M |
| Q4 '22 | 1.6M | 3.3M | -1.7M | -13M | -16M |
| Q3 '22 | 210,000 | 3.9M | -3.7M | -14M | -15M |
Insider Transactions
| MISSLING CHRISTOPHER U filed to sell 1,018,210 shares at $8. June 30 '23 |
Read more about Anavex Life Sciences and their earnings, price prediction, job posts, sentiment, webpage traffic, google adspend, google trends, patents, 4chan mentions, facebook engagement, facebook followers, stocktwits mentions, stocktwits subscribers, twitter followers, news mentions, reddit mentions, esg.